In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics ...

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Officials with the United Nations said Friday that more than 19,000 Palestinians had been displaced amid Israel's latest war ...

Danish pharmaceutical company Novo Nordisk A/S ... Jorgensen will continue as CEO “for a period to support a smooth transition to new leadership,” Novo said, adding that a search for a ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...